Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on January 17, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi215
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/2/113    most recent
hyi215v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kinugasa, Y.
Right arrow Articles by Saji, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinugasa, Y.
Right arrow Articles by Saji, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 Foundation for Promotion of Cancer Research
Received June 21, 2005
Accepted November 14, 2005

Case Report

Parathyroid Hormone-related Protein-Secreting Uterine Endometrioid Adenocarcinoma

Yoshitane Kinugasa 1, Ken-ichiro Morishige 1 *, Shoji Kamiura 1, Yoshitane Tsukamoto 2, and Fumitaka Saji 3

1 Department of Gynecology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka
2 Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka
3 National Hospital Organization, Kure Medical Center, Kure, Hiroshima, Japan

* To whom correspondence should be addressed.
Ken-ichiro Morishige, E-mail: ke{at}mc.pref.osaka.jp


  Abstract

The diagnosis of parathyroid hormone-related protein (PTHrP)-secreting metastatic uterine endometrioid cancer was made in a 32-year-old Japanese woman with humoral hypercalcemia of malignancy. The primary endometrial cancer had been removed, and the tumor was diagnosed as Grade 1 endometrioid adenocarcinoma with shallow myometrial invasion. Salvage chemotherapy (paclitaxel and calboplatin) was started from 5 months after surgery when recurrent tumors were detected in the peritoneum and liver. Despite the salvage chemotherapy, the tumor progressed and hypercalcemia became evident with elevated PTHrP whereas no bone metastasis was identified. To the best of our knowledge, this is the first reported case of hypercalcemia due to PTHrP secretion in uterine endometrioid adenocarcinoma.

Keywords: humoral hypercalcemia of malignancy; endometrioid adenocarcinoma; endometrialcancer; parathyroid hormone-related protein.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.